Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Walk through any pharmaceutical laboratory, and you run into dextrin’s legacy. This material, once a baker’s aid and textile filler, found its way into medicine thanks to some chance discoveries in enzyme chemistry in the early 19th century. French chemist Anselme Payen broke down starch into less complex carbohydrates, and his experiments completely shifted how starch derivatives could serve in human health. Over the years, improvements in purification and analytical techniques brought dextrin from its crude, yellowed beginnings into the highly purified, pharmaceutical-grade powder found in today's industry. Whole generations of chemical engineers refined production step by step, from potato and corn starches in the past to precise biological or acid hydrolysis processes now mapped out in GMP-compliant operations. This slow, technical progress pulled dextrin into a regulated world, aligning it to major pharmacopoeias like BP, EP, and USP. Each update to these standards told the story of rising purity demands and deeper scientific scrutiny, turning dextrin into more than a starch leftover—it now has a seat at the table in medicines people trust.
Dextrin, as applied in pharmaceutical contexts, shows up as a practical, nearly white to light yellow powder, blending ease of use with long-standing reliability. Chemically, this material derives from partially hydrolyzed starch—usually corn, sometimes wheat or potato. This partial hydrolysis leaves dextrin chains shorter than native starch and lighter on the palate, giving it a mild taste and smooth, free-flowing form. You see dextrin in so many tablet formulations because it binds ingredients together with consistency under pressure, resists moisture to some degree, and doesn’t bring unwanted chemical reactivity to most pharmaceutical active ingredients. Across the British, European, and United States Pharmacopeias, dextrin sold as BP EP USP Pharma Grade must meet detailed requirements for solubility, microbial limits, residue on ignition, and very low levels of heavy metals. These strict requirements guarantee patients only receive the cleanest, most consistent form, untouched by contaminants or unpredictable byproducts.
In my own lab work, dextrin stands out for its versatility in appearance and physical behavior. As a powder, it clumps less than many fillers, and when you rub it between your fingers, there’s hardly any grit—just a slightly smooth, almost creamy feel. Its color hovers around white, but old or poorly stored material yellow easily, warning you of moisture or thermal breakdown risks. On the solubility front, dextrin disperses quickly in cold water, forming thin solutions or mucilages, but never quite giving the thickening strength of full starch. This ability, to dissolve fully and clearly, plays a big role in oral suspension preparations or diluents, where clarity speaks to purity. Structurally, dextrin bridges the gap between simple sugars and bulkier polysaccharides, carrying a dextrose equivalent (DE) that ranks lower than pure glucose but higher than amylose or amylopectin. Its reaction to iodine—turning reddish-brown rather than blue—offers an easy field test, as well. Dextrin’s neutral flavor and stable pH make it more than just background filler; these features can preserve delicate actives, maintain product appearance, and avoid unwanted taste notes that turn patients away.
Look at any GMP-validated package of pharmaceutical dextrin, and you’ll see a block of technical data. Manufacturers must list batch number, expiration date, the origin species of starch, and detailed storage instructions—usually recommending cool, dry containment far from direct light. The specification sheet lays out carbon residue limits, foreign particle count, consistent molecular weight ranges, and verification by thin-layer or HPLC chromatography. Water content earns constant vigilance, with Karl Fischer titrations commonly used to ensure that the material stays below set moisture thresholds, usually about 7%. Every certificate of analysis confirms microbial absence, screening out pathogens like E. coli and Salmonella. Residual heavy metals, including lead and arsenic, stay well below the 1 ppm range, reflecting the demanding standards of current pharmacopeial chapters. Strict labeling rules also demand clarity over allergens, stating “gluten-free” if corn or potato serves as input, or highlighting wheat origins where relevant for patient safety.
Walking through an industrial dextrin facility, the sheer scale and precision become obvious. Starch starts as large wet cakes or dried powders, then flows into acid or enzyme reactors that trim down its chains under closely monitored heat and pH settings. Industrialists watch for temperature swings—sometimes no more than a few degrees—since too much can scorch the batch, leaving charred residues and off-flavors. Continuous batch testing monitors dextrose equivalent, seeking the golden zone between sticky sugar syrups and inert powdered starch. After hydrolysis, the mix passes through filtration and sometimes centrifugation, pulling out unreacted clumps and washing away soluble byproducts. Purification steps follow, using activated carbon to strip away color and strange tastes, then drying systems that drop moisture to stable levels. The result moves into controlled packing—polyethylene-lined, hermetic drums sealed to exclude oxygen and atmospheric water, with every step tracked for traceability.
Chemists constantly push to tweak dextrin’s properties. By adjusting acid or enzyme types, as well as reaction time, producers stretch or compress chain lengths, which tunes solubility and film-forming features. Further modifications, such as partial carboxymethylation or phosphate crosslinking, create dextrins that resist digestive enzymes, opening roles as dietary fiber additives or slow-release carriers. In some research, oxidized dextrins catch interest for their potential to chelate metals or serve as film-forming agents in transdermal patches. Because dextrin remains largely inert at ambient conditions, you rarely see unplanned chemical shifts—its appeal partly lies in this chemical predictability. Only under extreme acid or heat does dextrin break apart further, producing smaller sugars or Maillard reaction byproducts, which turn the product brown and sometimes promote off-flavors in delicate formulations.
Dextrin can turn up under a laundry list of alternate names, depending on the marketing or scientific focus. Calling it “British Gum” in older texts, or “Yellow Dextrin” in some specialty settings, points to its color or historical routes. On certificates or order forms, you sometimes see terms like “Pharmaceutical-Grade Dextrin,” “USP Compliant Dextrin,” or simply “Dextrini” in Latinized ingredient sections on packs approved for multiple jurisdictions. In the nutrition world, “maltodextrin” appears, though this term usually describes products with a higher dextrose equivalent and lighter color, more aimed at food or beverage applications. In specialty pharmaceutical compounding, “pre-gelatinized starch dextrin” specifies further processing that grants instant solubility, a feature especially important for liquid suspensions or instant-release tabs.
Pharmaceutical producers treat dextrin as a relatively safe and benign excipient, but not all risks disappear. Airborne powder may contribute to dust explosions—so facility design always includes advanced ventilation, explosion-suppression gear, and strict grounding protocols. Every production worker suits up with N95 masks and gloves, not just for comfort, but to cut down fire and particulate inhalation risks. As with most carbohydrates, dextrin rarely provokes adverse reactions. Still, trace gluten derivatives matter for sensitive populations, and regulatory authorities mandate separate production lines to avoid cross-contamination. Large-volume storage stays climate-controlled to fight caking or spontaneous fermentation from stray microbes. Even after years in storage, proper packaging and temperature management preserve dextrin’s function without major breakdown—one reason it remains a mainstay in stockrooms focusing on long-term stability.
Dextrin’s reach in pharma spans far beyond the role of mere filler. In my own work formulating pediatric dosages and instant-dissolve tablets, dextrin shows its strengths. As a binder, it helps turn loose powders into stable, dust-free tablets that press cleanly and break apart at just the right moment inside a patient’s mouth or gut. In coatings, dextrin lays down clear, smooth films that can mask taste or regulate the rate at which actives enter the stomach. Some wound dressings use dextrin to form a flexible, absorbent pad, offering a moist healing environment that discourages bacterial growth. For oral rehydration solutions, the ingredient manages both texture and caloric content, as dextrin passes almost invisibly through manufacturing processes. Veterinary drugs and nutritional supplements also take advantage of this profile, leveraging non-reactivity and allergen transparency to reach a wider population. Rarely have I seen a supply catalog without dextrin in a dozen forms, each tuned to an exacting blend or process, a testament to the material’s persistent relevance in healthcare delivery.
Modern R&D around dextrin pivots around modification and performance. Investigators in both academic and private labs explore chemically altered dextrins for new drug delivery platforms, aiming to attach small-molecule actives or optimize slow-release features using crosslinked architectures. Bioconjugation techniques take advantage of dextrin’s multiple hydroxyl groups, sticking on targeting peptides or imaging agents for diagnostic drugs. Recent studies push into controlled-release matrix tablets, where dextrin’s fine-tuned solubility and swelling behaviors allow slow, predictable liberation of actives over time. In some trials, researchers explore enzyme-resistant dextrins as prebiotics, seeking benefits for gut flora modulation without rapid digestion. Every few years brings fresh animal studies or clinical pilot programs that check new dextrin variants against toxicity, immunogenicity, and degradability benchmarks. Research groups aim for better analytical techniques, using tools like multi-angle light scattering and rapid NMR scans to untangle the fine structure of synthetic versus natural dextrins, and matching these traits to key outcomes for patient safety and effectiveness.
Few excipients enjoy the lengthy track record for low toxicity that dextrin does, but pharmacologists keep testing every batch. Oral acute, subchronic, and chronic toxicity tests in multiple animal models reinforce the material’s status as non-carcinogenic and minimally bioactive at the doses used in medicine. Studies in both rats and dogs, at doses many times higher than those found in actual products, generally report no change in weight, metabolism, or organ health even over extended periods. Some exceptions appear in cases of rapid fermentation in the gut, primarily when research uses extremely high-molecular-weight dextrins, but these effects show up far above therapeutic ranges. Immune response testing routinely measures serum markers after oral and injectable exposures, and reports rarely show allergic or inflammatory upticks. Experts do monitor for rare side effects, especially in immunocompromised patients or those with rare enzyme deficiencies, but the pharmacovigilance data over decades gives manufacturers solid ground for continued use, provided they stick to high purity and regulatory oversight.
The road ahead for dextrin looks promising, even as pharmaceutical science continues its ceaseless march toward specialization. Demand for modified dextrins with narrow molecular weight windows and designer reactivity grows, especially as biologics and personalized medicines require new delivery techniques and shelf-stable compositions. Sustainable sourcing exerts fresh pressure on starch input chains, pushing companies to prove traceability and avoid materials linked to GMO or high-pesticide crops, reflecting patient and environmental expectations. Smart packaging may extend product stability, relying on oxygen-absorbing liners or QR-code batch tracking to provide pharmacists with real-time quality data. Researchers hold out hope for smarter dextrin-based scaffolds in tissue engineering, or for new oral delivery forms that protect complex actives from stomach acid while releasing them only at defined points in the digestive tract. My own hope is that regulatory harmonization continues, so R&D teams in Europe, Asia, and the US can share discoveries, improve testing, and lock in dextrin’s place as a backbone of safe, reliable pharmaceutical design, ready to support the next wave of life-saving therapies.
Dextrin doesn’t make headlines, but walk behind the scenes in the pharmaceutical world and it lies everywhere—often silent, always steady. Its roots go back to plant starches. It gets used after careful processing, which follows the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) standards. Those labels mean companies trust it for consistency and safety. Quality matters in pharmaceuticals, and these standards let buyers know they’re getting the real deal—nothing less.
Pharma companies trust dextrin mainly because it holds things together. Most medicines people swallow every day come in tablet form. Making sure each pill has the same amount of medicine is not easy; the mix needs to stick together and break apart again in your stomach. Dextrin delivers on both fronts. Good tablets mean patients get the right amount of medication, no matter who opens the bottle.
Back on the production floor, dextrin shines as a binder in direct compression and wet granulation—the basic crafts of tablet making. I’ve spoken with folks in tablet development frustrated with cracking or crumbling pills; a switch to a consistent, pharma-grade dextrin often turns things around without fancy tricks or costly delays.
Not every active ingredient plays nice with moisture or heat. Some break down if exposed too long. Dextrin keeps many of these substances stable from mixing to packaging. People with allergies benefit too, since properly processed dextrin is usually non-allergenic if sourced from safe materials. Here’s one spot where quality matters; lower-grade dextrin may contain residuals that stir up trouble in sensitive patients.
Anyone who’s tried medicine as a kid knows many tablets taste awful. Dextrin helps mask bitter flavors and smoothen coatings. As a coating agent, dextrin gives tablets a finished, professional look, but more importantly, it makes them easier to swallow and less likely to stick in your throat. Taste, texture, and appearance all matter for patient compliance, particularly for kids and elders.
Dextrin enjoys a solid safety record and gets the green light across global regulatory agencies. That only comes with extensive toxicology studies and years of real-world data. No mystery ingredients, no corners cut. It’s become a favorite in both generic and branded medicines because risk-averse companies know they’re covered if they stick to BP/EP/USP standards.
Every ingredient brings baggage. Sourcing high-quality, sustainable dextrin starts with tracking raw materials—often from corn or potatoes. Innovations in traceability and greener manufacturing ease concerns about environmental impact and food chain competition. Transparent supply chains go hand in hand with pharma’s commitment to patient safety.
Increasing demand sometimes pushes manufacturers to cut corners or buy cheaper substitutes. Regular auditing, barcode tracking, and strict quality checks keep the real stuff in the mix. Anything less puts patients—and trust in modern medicine—at risk.
People rarely talk about the glue behind the pill. Dextrin pharma grade does its job quietly, holding medicines together, helping with taste, and meeting tough regulatory demands. It’s easy to overlook these building blocks until something goes wrong. I’ve seen the value of reliable excipients first-hand, watching teams solve tough tablet-crafting problems using just a better grade of dextrin.
Dextrin keeps cropping up across the pharmaceutical world. It’s a carbohydrate, often made from starch, that gets used in lots of tablets and capsules. Anyone working in pharmacy labs or reading drug labels has seen these three key letters—BP, EP, and USP—tied to dextrin. Those stand for British Pharmacopoeia, European Pharmacopoeia, and United States Pharmacopeia. Each standard spells out exactly what kind of dextrin counts as pharma grade.
Companies need strict guidelines because patients rely on medicines to be both safe and consistent. Regulations make sure that dextrin for pharmaceuticals leaves behind the contaminants found in cheaper, industrial grades. Every certified batch goes through tests for purity, residual solvents, and even moisture content. Contaminants or bacteria can wreck a whole production line or worse—harm someone relying on medication. Dextrin for pills needs to come from suppliers following pharmaceutical-grade processes, not those spinning up cheaper versions for the food or paper industry.
Most people handle dextrin without problems. Still, some may have issues, especially if allergic to the source starch. Corn, potato, and wheat are common starting points, so the raw ingredient matters. The labeling standards for pharma grade help healthcare professionals track down the origin and catch allergies before they become problems.
Dextrin does more than just fill space. It binds powders together in tablets, helps medicine dissolve, and ensures each dose puts out the right active ingredient. Those roles aren’t just background work—they’re critical. Badly performing excipients can send patients to the ER due to dosing errors or spoiled tablets. Dextrin stands out for being stable, food-safe, and able to blend well, which makes it a top pick for pill makers.
Every credible supplier provides paperwork showing batches pass BP, EP, or USP checks. They also support traceability, meaning every step from starch to pill is documented. Audits help spot problems early and clamp down on shortcuts that could slip impurities into the mix. If a distributor can’t provide this documentation, that raises a red flag.
The pharma world is always chasing higher safety. Demand for even cleaner dextrin keeps manufacturers on their toes. Better testing for microcontaminants, faster allergen screening, and more transparent sourcing could push safety even higher. Partners who share lot data and work closely with regulators help keep quality on track.
Safety in excipients like dextrin doesn’t just rest on a single company’s shoulders. Regulators, suppliers, pharmacists, and patients play a part in keeping each medicine on the safe side. Recognizing trusted supply chains, choosing certified materials, and reporting issues quickly all help keep dextrin safe in tablets and capsules.
Walking through a pharmaceutical lab, the jars are often lined with substances you’d never think twice about. Dextrin mostly goes unnoticed, but it plays a crucial role. It isn’t just tossed in as a powder to take up space—its purpose shows up in everything from tablet sticking power to dissolving rates. Anyone handling medication understands that basic starch can’t cut it when working to the fine tolerances demanded by medicine. Dextrin offers the required purity, batch consistency, and safety that regular food or industrial starch never matches.
Too many people lump all dextrin into a single pile. Dextrin for pharmaceuticals comes in British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) grades. Meeting these standards means the product has to pass some of the strictest global checks. In the lab, nobody wants to waste a batch because a "pure" substance carried impurities. BP, EP, and USP guidelines act like a guarantee that what shows up in the bag is suitable for medicine meant for human use.
Testing doesn’t involve just glancing at a chemical assay. Heavy metal levels must stay below precise limits: lead under 2 parts per million, arsenic below 2 ppm, and iron below 30 ppm. Microbial purity isn’t optional. Pathogens—E. coli, Salmonella, Staphylococcus—must never show up. The loss on drying has to be under 15%, preventing mold or caking. Dextrin’s solubility also matters. Pharmaceutical-grade dextrin should dissolve clear in water, leaving nothing gritty or cloudy behind.
Ignoring these specs brings costly problems. Production managers can tell horror stories about contamination that ruined entire batches and set projects back weeks. In my experience, even the subtlest off-spec impurity—an extra trace of silicon, a slight discoloration—can mean re-testing, and sometimes a full recall. It doesn’t feel like overkill to demand traceability. I’ve seen smart operators ask suppliers for full certificates of analysis, batch numbers, and microbial testing records before signing off on an order.
Many companies turn to outside labs for regular third-party verification. Investment in better in-house rapid testing also pays off. Training staff to spot visual changes—clumping, yellowing, odd odor—helps catch the outliers early. Importers who bring in raw material without these steps risk choking their whole production line.
Trust goes both ways. Supplier audits with open books build relationships that last years, not months. I’ve visited plants overseas where workers take tonight’s shipment as seriously as a job interview. These partnerships turn specs on a sheet into real life quality—every batch, every shipment, every time.
Dextrin for pharmaceutical use isn’t just any starch derivative. Regulators expect every bag to deliver batch-to-batch consistency, with zero room for error. So, how it’s kept in storage isn’t an afterthought. Cleanliness, dryness, and proper temperature control matter from the first delivery onward. I’ve seen labs run into headaches—not from technical errors, but from letting a shed or back room take the place of proper storage. That's a shortcut nobody wants to risk.
Dextrin pulls in moisture like a sponge, and it doesn’t take much humidity for clumping or even microbial growth to start. Even a slightly damp storeroom can turn a good batch to waste. Labs with strict quality standards always use sealed containers—plastic drums with gasketed lids work well. Keeping the product dry is about more than preventing ruined powder; any contamination can compromise a whole lot more than one batch, especially if a cross-contaminant finds its way into tablet production.
People hear “cool, dry place” and tune out, but the difference between 40°C and 20°C can separate an accepted batch from a rejected one. High temperature speeds up all the wrong kinds of chemical reactions. Dextrin isn’t explosive, but it will start breaking down and lose the quality control markers expected by pharmacopeia standards. I’ve worked in facilities where even short-term heat spikes would affect annual inspection results. Keeping storage spaces below 25°C, away from direct sunlight, is about protecting both product and patient.
Open storage is an invitation for dust, insects, and accidental spillages. Labs that take contamination seriously keep Dextrin off the ground, in closed storage, and out of food handling zones. Every product batch gets logged, dated, and kept in cleanable racks. More than once, I’ve seen mid-sized facilities knock down their costs simply by investing in racks and routine pest inspections, avoiding contamination that costs much more to clean up after the fact.
Every drum or bag looks the same at a glance, but improper tracking invites expiration surprises or, worse, product mix-ups. Pharmaceutical-grade dextrin has a limited shelf life, so product rotation is as important as any labelling. No one forgets the first audit that uncovers unlabeled or undated containers stacked out of sight. That tends to bring a policy change overnight.
Practical storage means sealed packaging, dry and cool rooms, raised shelving, clear labels, and proper inventory. These aren’t just bureaucratic steps—they’re habits that differentiate a pharmaceutical operation from a risky guesswork shop. Keeping the risks down and quality up always comes back to what happens long before a production run starts.
Dextrin, that reliable starch-based excipient found throughout the pharmaceutical world, often doesn’t get talked about unless it’s missing from a supplier’s inventory. Most pharmaceutical and research labs want predictability, especially with something that quietly underpins tablet production and powder blends. Looking around at what’s standard, 25-kilogram fiber drums show up time and again, often lined with a polyethylene bag to guard against moisture. Sometimes, smaller 5-kilogram or 10-kilogram packs keep material handling under control in smaller facilities or research groups. I’ve lugged both sizes through crowded storerooms, and the difference between a rigid drum and a tear-prone sack really hits home after a shipping mishap. Users may like the flexibility of these options, but consistency and protection from contaminants stand out as the top priorities.
Most pharmaceutical-grade dextrin sticks to a shelf life of about three years. The industry marks “best before” dates for good reason. Dextrin loves to attract water from the air, and if humidity sneaks past that inner liner, clumping can happen fast, often spoiling batches or tool performance long before the actual expiry comes around. I remember a few cases where product loss resulted from ignored storage instructions. According to published specs and supplier data, unopened and properly stored dextrin—cool, dry, and sealed—keeps its performance through that full three-year window. But as soon as bags are opened, risk rises, and there’s pressure to finish the drum quickly or transfer what’s left into airtight containers.
Pharma production runs get thrown off by one contaminated or degraded excipient. It takes only a subtle rise in water content to throw off dissolution times or make powders cake together. Strict inventory rotation, as practiced in facilities with good control systems, protects against “old batch” surprises. From my own experience with periodic stock checks, even a few months can mean a noticeable shift in flow if operators miss standard checks. For this reason, smaller packaging sometimes wins out in high-turnover environments—a fresh, freshly opened bag often brings peace of mind over dipping into a half-used drum.
Caring for dextrin after shipment makes a big difference. Any pharma-quality batch needs to be kept off the floor, away from sunlight, and away from humidity sources. Temperature swings are the enemy of shelf life. One facility I worked with insisted on double-bagging open drums, storing them in temperature-monitored cages—a hassle at first, but much less lost product in the long run.
Many buyers look for added data: clear labeling with manufacture date, batch traceability, and real-time shelf life tracking. Suppliers who offer packaging suited to both frequent and occasional use—like air-tight pails, sturdy drums, or resealable bags—make life easier for everyone who needs to trust the materials every step of the way. As regulations evolve, transparency in shelf life testing and handling instructions only gets more important.
Product quality depends on the details—from how dextrin is packed to how it’s handled in storage. Simple choices in packaging and storage add up to bigger savings and fewer headaches, both for manufacturers and the people downstream who depend on safe, reliable products.
| Names | |
| Preferred IUPAC name | Maltodextrin |
| Other names |
British Dextrin Yellow Dextrin Soluble Starch Dextrine Amylodextrin Pharmaceutical Dextrin |
| Pronunciation | /ˈdɛkstrɪn ˌbiːˈpiː ˌiːˈpiː ˌjuːˌɛsˈpiː ˈfɑːrmə ɡreɪd/ |
| Identifiers | |
| CAS Number | 9004-53-9 |
| Beilstein Reference | 3495255 |
| ChEBI | CHEBI:28600 |
| ChEMBL | CHEMBL1201578 |
| ChemSpider | 23248152 |
| DrugBank | DB09463 |
| ECHA InfoCard | ECHA InfoCard: 03-2119448720-46-0000 |
| EC Number | 9004-53-9 |
| Gmelin Reference | 47357 |
| KEGG | C00147 |
| MeSH | Dextrins"[MeSH] |
| PubChem CID | 439204 |
| RTECS number | VI5950000 |
| UNII | 6R1V15T3SU |
| UN number | Dextrin BP EP USP Pharma Grade" does not have a UN number. |
| CompTox Dashboard (EPA) | CompTox Dashboard (EPA) of product 'Dextrin BP EP USP Pharma Grade' is "DTXSID7022725 |
| Properties | |
| Chemical formula | (C6H10O5)n |
| Molar mass | 162.14 g/mol |
| Appearance | White or yellowish, odorless, amorphous powder |
| Odor | Odorless |
| Density | Dextrin BP EP USP Pharma Grade has a density of approximately 0.6 to 1.0 g/cm³. |
| Solubility in water | Freely soluble in water |
| log P | -3.1 |
| Basicity (pKb) | 10.2 |
| Magnetic susceptibility (χ) | Diamagnetic |
| Refractive index (nD) | 1.47 |
| Viscosity | 100 to 200 cps |
| Pharmacology | |
| ATC code | A14CX |
| Hazards | |
| GHS labelling | GHS07, Warning, H335, H319, P261, P305+P351+P338 |
| Pictograms | GHS07 |
| Signal word | Not Hazardous |
| Hazard statements | Not a hazardous substance or mixture. |
| NFPA 704 (fire diamond) | 1-0-0 |
| Autoignition temperature | 210°C |
| LD50 (median dose) | > 16,000 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | 10 mg/m3 |
| REL (Recommended) | Store in a cool, dry place in tightly closed containers. |
| Related compounds | |
| Related compounds |
Maltodextrin Cyclodextrin Starch Pregelatinized Starch Hydroxypropyl Starch Amylose Amylopectin Modified Starch |
Chengguan District, Lanzhou, Gansu, China
